Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.

Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE.

Nat Med. 2010 Dec;16(12):1414-20. doi: 10.1038/nm.2236. Epub 2010 Nov 7.

2.

Trimming of mammalian transcriptional networks using network component analysis.

Tran LM, Hyduke DR, Liao JC.

BMC Bioinformatics. 2010 Oct 13;11:511. doi: 10.1186/1471-2105-11-511.

3.

Identification of a cell of origin for human prostate cancer.

Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON.

Science. 2010 Jul 30;329(5991):568-71. doi: 10.1126/science.1189992.

4.

Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures.

Plaisier SB, Taschereau R, Wong JA, Graeber TG.

Nucleic Acids Res. 2010 Sep;38(17):e169. doi: 10.1093/nar/gkq636. Epub 2010 Jul 21.

5.

Integrative genomic profiling of human prostate cancer.

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL.

Cancer Cell. 2010 Jul 13;18(1):11-22. doi: 10.1016/j.ccr.2010.05.026. Epub 2010 Jun 24.

6.

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM.

PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547.

7.

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM.

Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.

8.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14.

9.

PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.

Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F.

Cell Oncol. 2010;32(1-2):11-27. doi: 10.3233/CLO-2009-0487.

10.

Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells.

Yuan H, Young CY, Tian Y, Liu Z, Zhang M, Lou H.

Mol Cell Biochem. 2010 Jun;339(1-2):253-62. doi: 10.1007/s11010-010-0388-7. Epub 2010 Feb 11.

PMID:
20148354
11.

Emerging role of FKBP51 in AKT kinase/protein kinase B signaling.

Pei H, Lou Z, Wang L.

Cell Cycle. 2010 Jan 1;9(1):6-7. Epub 2010 Jan 9. No abstract available.

PMID:
20016266
12.

Steroid hormone receptors in prostate cancer: a hard habit to break?

Attard G, Cooper CS, de Bono JS.

Cancer Cell. 2009 Dec 8;16(6):458-62. doi: 10.1016/j.ccr.2009.11.006.

13.

Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model.

Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H.

Cancer Res. 2009 Nov 15;69(22):8555-62. doi: 10.1158/0008-5472.CAN-08-4673. Epub 2009 Nov 3.

14.

Is EGR1 a potential target for prostate cancer therapy?

Gitenay D, Baron VT.

Future Oncol. 2009 Sep;5(7):993-1003. doi: 10.2217/fon.09.67. Review.

15.

Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.

Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, Laskey J, Bettano KA, Kasibhatla S, Reilly JF, Sur C, Majumder PK.

Cancer Res. 2009 Sep 15;69(18):7466-72. doi: 10.1158/0008-5472.CAN-08-4385. Epub 2009 Sep 8.

16.

FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L.

Cancer Cell. 2009 Sep 8;16(3):259-66. doi: 10.1016/j.ccr.2009.07.016.

17.

Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.

Ham WS, Cho NH, Kim WT, Ju HJ, Lee JS, Choi YD.

J Urol. 2009 Oct;182(4):1378-84. doi: 10.1016/j.juro.2009.06.025. Epub 2009 Aug 14.

PMID:
19683286
18.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Review.

19.

Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.

Simanainen U, McNamara K, Gao YR, Handelsman DJ.

Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1335-43. doi: 10.1152/ajpendo.00017.2009. Epub 2009 Apr 14.

20.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.

Items per page

Supplemental Content

Write to the Help Desk